NIAID launched the STOMP trial to determine whether the antiviral drug tecovirimat can safely and effectively treat mpox. Watch Dr. Cyrus Javan of NIAID's Division of AIDS explain the importance of the STOMP trial.
With ticks expanding their territories in many parts of the world, a NIAID research group has likewise expanded its promising vaccine research to two typically rare pathogens with potential for public health importance -- Kyasanur Forest disease and Alkhurma hemorrhagic fever.
A team of vaccine production experts from South Africa recently finished training with NIAID Vaccine Research Center scientists. Their objective: to globally produce vaccines against a list of troubling infectious diseases.
Viral hepatitis is an inflammatory liver disease caused by infection with any of the known hepatitis viruses—A, B, C, D, and E. Most of the global viral hepatitis burden is from hepatitis B and C, which affect 354 million people and result in 1.1 million deaths annually. The Centers for Disease Control and Prevention estimates that in 2020 there were 14,000 and 50,300 new acute infections of...
This blog is cross-posted from HIV.gov.
On Tuesday at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), HIV.gov continued our conversations about research highlights, including a focus on the latest about HIV vaccines. We also heard an update from the NIH Office of AIDS Research.
NIH’s Carl Dieffenbach, Ph.D., Director of the Division of AIDS at the National Institute...
NIAID scientists and colleagues are one step closer to developing a safe and effective therapy against alphaviruses, which are spread by mosquitoes and can cause two types of disease in people: causing severe neurological impairment such as encephalitis (brain swelling) or crippling muscle pain similar to arthritis.
Register now to take part in an important conversation about National HIV Vaccine Awareness Day—an annual observation to recognize the many community members, health professionals, and scientists working together to develop a vaccine to prevent HIV. The HIV.gov-hosted Live with Leadership conversation will take place on Thursday, May 18, from 2:30–3:00pm ET.
Developing a universal influenza vaccine is a significant priority for NIAID scientists. Two new studies describe a unique candidate developed by NIAID's Vaccine Research Center that performed well in a Phase 1 clinical trial.
Two recently published studies explain why some people respond better to vaccines than others and could guide the development of new strategies to enhance the antibody response to vaccination.
As scientists learn more about SARS-CoV-2 and its infection tactics, nasal vaccines appear to be a promising response.
Developing a vaccine capable of fighting a diverse group of coronaviruses and viral variants remains a priority for NIAID, which NIAID has awarded an additional $26.1 million for four additional “pan-coronavirus” vaccine grant awards,
The National Institutes of Health has awarded approximately $34 million annually over the next five years to fund six independent Centers for HIV Structural Biology
An investigational typhoid vaccine containing a component developed with NIAID funding may overcome some of the shortcomings of available typhoid vaccines, according to a paper published in the journal Vaccine in June.
A new comparison study in PNAS from NIAID intramural scientists clearly shows that for SARS-CoV-2, nasal vaccination – particularly in two doses – has clear advantages over muscular delivery in laboratory mice.
NIAID investigators recently published initial results from a study seeking to characterize and better understand persistent symptoms some people experience after having COVID. These persistent symptoms, often referred to as “long COVID,” can sometimes be debilitating, and their cause is currently unknown. This single-site study is part of a larger research effort across multiple institutes at NIH and NIH-funded institutions to understand, prevent, and treat long-term health effects related to COVID-19.
The national EV-D68 pilot study is part of PREMISE, the Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology. PREMISE is an initiative from NIAID’S Vaccine Research Center (VRC) that began in early 2021.
Today marks the 25th anniversary of the first HIV Vaccine Awareness Day. Although tremendous progress has been made over the past several decades in HIV treatment and prevention, the development of a safe, effective, and durably protective vaccine to prevent HIV infection has, unfortunately, remained elusive. On this commemorative day, NIAID acknowledges the disappointments of the past while optimistically looking ahead to what’s next in HIV vaccine development.
NIH’s Dr. Carl Dieffenbach Discusses Highlights of HIV Cure, Treatment and Prevention Research from CROI 2022
In an HIV.gov video conversation on February 16, NIAID's Dr. Carl Dieffenbach discussed some of the pivotal HIV research advances presented this week at the 2022 virtual Conference on Retroviruses and Opportunistic Infections (CROI 2022). Dr. Dieffenbach, who directs the Division of AIDS, covered developments in HIV cure, treatment and prevention research. Watch the conversation and read summaries of the study findings he discussed.
While implementation of highly effective HIV treatment and prevention tools has reduced the HIV pandemic worldwide, development of a safe and even modestly effective vaccine would hasten progress toward a durable end of the HIV pandemic. Today, on HIV Vaccine Awareness Day, NIAID acknowledges both the progress that has been made in HIV vaccine development and the challenges that remain. We also reflect on how advances in HIV vaccinology paved the way for COVID-19 vaccine development.
Single-dose experimental COVID-19 vaccine delivered into the nose of rhesus macaques protected lungs and nasal regions from SARS-CoV-2 infection.
A vaccine developed to protect broadly against Mosquito-borne diseases appears safe in Phase 1 of a NIAID trial.
A safe and effective HIV vaccine remains elusive. On HIV Vaccine Awareness Day 2020, NIAID honors researchers and clinical study participants.
A NIAID-led trial has proven an experimental chikungunya vaccine to be both safe and to confer durable immune responses in healthy volunteers.
A candidate vaccine delivered though a thumbnail-sized patch studded with microneedles could help address the coronavirus disease 2019 (COVID-19) pandemic.
NIAID reiterates commitment to researching tuberculosis, the world’s leading cause of death from a single infectious disease.